Actively Recruiting
The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis
Led by Asan Medical Center · Updated on 2026-03-27
2340
Participants Needed
24
Research Sites
142 weeks
Total Duration
On this page
Sponsors
A
Asan Medical Center
Lead Sponsor
K
Korea Otsuka Pharmaceutical Co., Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
Currently, aspirin plus clopidogrel is considered as a standard acute treatment of ischemic stroke, based on results of CHANCE and POINT trial. However, still a considerable portion of patients showed early stroke recurrence, especially in those with stroke due to large artery atherosclerosis. Cilostazol may have benefit in reducing early stroke recurrence of neurologic deterioriation. The post-hoc analysis of CSPS.com showed that use of cilostazol after 15 days of stroke was effective for preventing subsequent stroke. The effect of adding cilostazol was more effective in those with large artery atherosclerosis and those receiving clopidogrel than aspirin.
CONDITIONS
Official Title
The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age of 20 years or older
- Acute ischemic stroke due to large artery atherosclerosis confirmed by imaging showing ischemic lesion and significant stenosis (more than 50% diameter reduction)
- Ability to provide informed consent within 72 hours of stroke onset
- Written informed consent obtained prior to study entry
You will not qualify if you...
- Large infarction preventing start of antiplatelet treatment
- Acute intracranial hemorrhage present
- Initial hemorrhagic transformation
- Previous modified Rankin Scale score higher than 2
- Indicated for anticoagulation therapy
- Contraindications to aspirin, clopidogrel, or cilostazol
- Need for long-term nonsteroidal anti-inflammatory drugs
- Planned surgery before or during study
- Unable to withdraw consent
- Investigator judges participant unable to participate
- Participants of reproductive potential who do not agree to birth control or abstinence
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 24 locations
1
Asan Medical Center
Seoul, Songpa-gu, South Korea, 05505
Actively Recruiting
2
Pusan National University Hospital
Busan, South Korea
Actively Recruiting
3
Chungbuk National University Hospital
Cheongju-si, South Korea
Actively Recruiting
4
Kyungpook National University Chilgok Hospital
Daegu, South Korea
Actively Recruiting
5
Chungnam National University Hospital
Daejeon, South Korea
Actively Recruiting
6
Eulji University Hospital
Daejeon, South Korea
Actively Recruiting
7
Chonnam National University Hospital
Gwangju, South Korea
Actively Recruiting
8
Seoul National University Bundang Hospital
Gyeonggi-do, South Korea, 13620
Actively Recruiting
9
Hallym University Medical Center
Gyeonggi-do, South Korea
Actively Recruiting
10
Hanyang University Guri Hospital
Gyeonggi-do, South Korea
Actively Recruiting
11
Korea University Ansan Hospital
Gyeonggi-do, South Korea
Actively Recruiting
12
Gachon University Gil Medical Center
Incheon, South Korea, 21565
Actively Recruiting
13
Inha University Hospital
Incheon, South Korea
Actively Recruiting
14
Jeju National University Hospital
Jeju City, South Korea
Actively Recruiting
15
Jeonbuk National University Hospital
Jeonju, South Korea
Actively Recruiting
16
Ewha Womans University Seoul Hospital
Seoul, South Korea
Actively Recruiting
17
Hanyang University Seoul Hospital
Seoul, South Korea
Actively Recruiting
18
Korea University Guro Hospital
Seoul, South Korea
Actively Recruiting
19
Kyung Hee University Hospital at Gangdong
Seoul, South Korea
Actively Recruiting
20
Kyung Hee University Hospital
Seoul, South Korea
Actively Recruiting
21
Samsung Medical Center
Seoul, South Korea
Actively Recruiting
22
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, South Korea
Actively Recruiting
23
Yonsei University Health System, Gangnam Severance Hospital
Seoul, South Korea
Not Yet Recruiting
24
Pusan National University Yangsan Hospital
Yangsan, South Korea
Actively Recruiting
Research Team
B
Bum Joon Kim, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here